Last Price$2.02Cboe Previous Close - Real-Time Last Sale as of 4:01PM ET 6/24/22
Cboe Real-Time Quotes
Today's Change0(0.00%)
Bid (Size)$1.98 (1,000)
Ask (Size)$2.38 (2)
Day Low / HighN/A - N/A
Volume762.1 K

View Pharmaceuticals: Major IndustryPeer Comparison as of 06/24/2022


Otonomy Inc ( NASDAQ )

Price: $2.02
Change: 0.00 (0.00%)
Volume: 762.1 K
4:01PM ET 6/24/2022

AquaBounty Technologies Inc ( NASDAQ )

Price: $1.62
Change: -0.09 (5.26%)
Volume: 8.1 M
4:00PM ET 6/24/2022

Paratek Pharmaceuticals Inc ( NASDAQ )

Price: $2.12
Change: -0.02 (0.93%)
Volume: 5.9 M
4:00PM ET 6/24/2022

Homology Medicines Inc ( NASDAQ )

Price: $2.03
Change: -0.22 (9.78%)
Volume: 4.9 M
4:00PM ET 6/24/2022

Viracta Therapeutics Inc ( NASDAQ )

Price: $2.96
Change: +0.26 (9.63%)
Volume: 4.4 M
4:00PM ET 6/24/2022

Read more news Recent News

-- Earnings Flash (OTIC) OTONOMY Reports Q1 Loss $-0.20, vs. Street Est of $-0.20
4:24PM ET 5/09/2022 MT Newswires


--Oppenheimer Adjusts Otonomy Price Target to $6 From $5, Maintains Outperform Rating
12:51PM ET 4/21/2022 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Otonomy Says Hearing Loss Treatment Drug Showed Clinical Benefit During Phase 2a Trial
7:57AM ET 4/20/2022 MT Newswires

Otonomy (OTIC) said Wednesday that its OTO-413 drug showed clinically meaningful treatment benefit in patients with hearing loss during a phase 2a trial. ...

-- Earnings Flash (OTIC) OTONOMY Posts Q4 Loss $-0.20, vs. Street Est of $-0.18
4:28PM ET 2/28/2022 MT Newswires


Company Profile

Business DescriptionOtonomy, Inc. operates as a biopharmaceutical company. engages in the development of therapeutics for neurotology. The firm’s product pipeline includes OTIVIDEX (dexamethasone) Meniere's disease, OTIPRIO (ciprofloxacin otic suspension) acute otitis media with tubes (AOMT), OTO-313 (gacyclidine) tinnitus, OTO-413 (BDNF) hidden hearing Loss, OTO-510 (otoprotectant) prevent CIHL, OTO-6XX (hair cell regeneration) severe hearing loss. It operates under the Otiprio brand. The company was founded by Jay B. Lichter, Jeffrey Harris, Rick Friedman, and Allen F. Ryan on May 6, 2008 and is headquartered in San Diego, CA. View company web site for more details
Address4796 Executive Drive
San Diego, California 92121
Number of Employees49
Recent SEC Filing06/23/20224
President, Chief Executive Officer & DirectorDavid A. Weber
Vice President -Technical operationsAnna Stepannenko
Chief Financial & Business OfficerPaul E. Cayer
Vice President-Research & Preclinical DevelopmentFabrice Piu

Company Highlights

Price Open$1.96
Previous Close$2.02
52 Week Range$1.14 - 2.59
Market Capitalization$115.0 M
Shares Outstanding56.9 M
SectorHealth Technology
IndustryPharmaceuticals: Major
Next Earnings Announcement08/03/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$0.78
Beta vs. S&P 500N/A
Revenue$745.0 K
Net Profit Margin-150,065.71%
Return on Equity-86.69%

Analyst Ratings as of 11/11/2021

Consensus RecommendationConsensus Icon
Powered by Factset